RxDoctor Payments Data

Heli Niemi, MD

Family Medicine · Plano, TXNPI 1477525236

Payments from drug & device makers

$2,312in general payments, 2019–2025

Across 143 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$378
  • Pfizer$305
  • Novo Nordisk$302
  • GSK$227
  • AbbVie$121
  • Biohaven Pharmaceuticals, Inc.$97
  • plus $882 from 24 others

What the payments were for

  • Food & beverage$2,312100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,312 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$74,672
Medicare patients
226
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin157$151,402
OzempicSemaglutide79$80,637
EliquisApixaban39$36,348
MyrbetriqMirabegron23$21,205
MounjaroTirzepatide16$19,549
FarxigaDapagliflozin Propanediol15$17,384
RybelsusSemaglutide11$12,950
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$12,293
VascepaIcosapent Ethyl23$11,426
Breo ElliptaFluticasone/Vilanterol19$11,011
BelsomraSuvorexant17$8,262
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,887
Humalog Kwikpen U-200Insulin Lispro11$4,515
SynthroidLevothyroxine Sodium42$4,409
Novolog FlexpenInsulin Aspart13$3,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$57$151,402157 claims
Novo NordiskOzempic, Rybelsus$302$93,58790 claims
PfizerEliquis$305$36,34839 claims
GSKAnoro Ellipta, Breo Ellipta, Trelegy Ellipta$227$31,19144 claims
Lilly USA, LLCMounjaro$12$19,54916 claims
AstraZenecaFarxiga$378$17,38415 claims
MerckBelsomra$62$8,26217 claims
AbbVieSynthroid$121$4,40942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →